José Damas

José Damas

Auto-generated profile, based on publicly available information

José Damas

Infectious Diseases Service University Hospital Lausanne, University of Lausanne Lausanne Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2024 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JDJosé Damas
José Damas
AMAline Munting
Aline Munting
JFJacques Fellay
Jacques Fellay
DHDavid Haerry
David Haerry
Catia MarzoliniCatia Marzolini
Catia Marzolini
BSBernard Surial
Bernard Surial
Background: Antiretroviral therapy (ART)-related weight gain is of particular concern in people with HIV (PWH). Although weight gain was observed among PWH receiving tenofovir alafenamide (TAF), little is known about the potential reversibility after TAF discontinuation. We evaluated weight and metabolic changes 12 months after TAF discontinuation in the Swiss HIV Cohort Study. Methods: We included participants who received at least 6 months of TAF-containing ART between January 2016 and March 2023. Using multivariable mixed-effect models, changes in weight and lipid levels were compared between individuals who continued TAF and those who switched to one of the following TAF-free regimens: (1) tenofovir disoproxil fumarate (TDF)-based ART, (2) dolutegravir/lamivudine (DTG/3TC), or (3) long-acting cabotegravir/rilpivirine (CAB/RPV). Results: Of 6555 participants (median age 54 years, 24.3% female, 13% Black), 5485 (83.7%) continued, and 1070 (16.3%) stopped TAF. Overall, discontinuing TAF was associated with an adjusted mean weight change of −0.54 kg (95% confidence interval [CI] −.98 to −.11) after 12 months. In stratified analyses, switching from TAF to TDF led to an adjusted mean weight decrease of −1.84 kg (95% CI −2.72 to −.97), and to a decrease in mean total cholesterol (−0.44 mmol/L) and triglycerides (−0.38 mmol/L) after 12 months. Switching from TAF-based ART to DTG/3TC (−0.17 kg, 95% CI −.82 to .48) or long-acting CAB/RPV (−0.64 kg, 95% CI −2.16 to .89) did not lead to reductions in weight. Conclusions: Replacing TAF with TDF in PWH led to a decrease in body weight and an improved lipid profile within 1 year. Weight changes were not observed among individuals who switched to DTG/3TC or long-acting CAB/RPV.

25 March 2025 in Clinical Infectious Diseases
Verified
Journal Article
Open access
LBLena Bartl
Lena Bartl
MZMarius Zeeb
Marius Zeeb
MKMarisa Kälin
Marisa Kälin
TLTom Loosli
Tom Loosli
JNJulia Notter
Julia Notter
JNJohannes Nemeth
Johannes Nemeth
Background: Coinfections of Mycobacterium tuberculosis (MTB) and human immunodeficiency virus (HIV) impose a substantial global health burden. Patients with MTB infection face a heightened risk of progression to incident active TB, which preventive therapy can mitigate. Current testing methods often fail to identify individuals who subsequently develop incident active TB. Methods: We developed random forest models to predict incident active TB using patients' medical data at HIV-1 diagnosis. Training our model involved using clinical data routinely collected at enrollment from the Swiss HIV Cohort Study (SHCS). This dataset encompassed 55 people with HIV (PWH) who developed incident active TB 6 months after enrollment and 1432 matched PWH without TB enrolled between 2000 and 2023. External validation used data from the Austrian HIV Cohort Study, comprising 43 people with incident active TB and 1005 people without TB. Results: We predicted incident active TB with an area under the receiver operating characteristic curve of 0.83 (95% CI: .8–.86) in the SHCS. After adjusting for ethnicity and the region of origin and refitting the model with fewer parameters, we obtained comparable receiver operating characteristic curve values of 0.72 (SHCS) and 0.67 (Austrian HIV Cohort Study). Our model outperformed the standard of care (tuberculin skin test and interferon-gamma release assay) in identifying high-risk patients, demonstrated by a lower number needed to diagnose (1.96 vs 4). Conclusions: Models based on machine learning offer considerable promise for improving care for PWH, requiring no additional data collection and incurring minimal additional costs while enhancing the identification of PWH that could benefit from preventive TB treatment.

8 March 2023 in HIV Medicine
Verified
Journal Article
Open access
JDJosé Damas
José Damas
KDKatharine E. A. Darling
Katharine E. A. Darling
PBPhanie Bidlingmeyer
Phanie Bidlingmeyer
INIsaure Nadin‐Debluë
Isaure Nadin‐Debluë
MBMélanie Bieler
Mélanie Bieler
MCMatthias Cavassini
Matthias Cavassini
Background: With ageing, comorbidities such as neurocognitive impairment increase among people living with HIV (PLWH). However, addressing its multifactorial nature is time‐consuming and logistically demanding. We developed a neuro‐HIV clinic able to assess these complaints in 8 h using a multidisciplinary approach.Methods: People living with HIV with neurocognitive complaints were referred from outpatient clinics to Lausanne University Hospital. Over 8 h participants underwent formal infectious disease, neurological, neuropsychological and psychiatric evaluations, with opt‐out magnetic resonance imaging (MRI) and lumbar puncture. A multidisciplinary panel discussion was performed afterwards, with a final report weighing all findings being produced.Results: Between 2011 and 2019, a total of 185 PLWH (median age 54 years) were evaluated. Of these, 37 (27%) had HIV‐associated neurocognitive impairment, but they were mainly asymptomatic (24/37, 64.9%). Most participants had non‐HIV‐associated neurocognitive impairment (NHNCI), and depression was prevalent across all participants (102/185, 79.5%). Executive function was the principal neurocognitive domain affected among both groups (75.5% and 83.8% of participants impaired, respectively). Polyneuropathy was found in 29 (15.7%) participants. Abnormalities in MRI were found in 45/167 participants (26.9%), being more common among NHNCI (35, 77.8%), and HIV‐1 RNA viral escape was detected in 16/142 participants (11.2%). Plasma HIV‐RNA was detectable in 18.4% out of 185 participants.Conclusions: Cognitive complaints remain an important problem among PLWH. Individual assessment from a general practitioner or HIV specialist is not enough. Our observations show the many layers of HIV management and suggest that a multidisciplinary approach could be helpful in determining non‐HIV causes of NCI. A 1‐day evaluation system is beneficial for both participants and referring physicians.

24 August 2023 in HIV Medicine
Verified
Journal Article
Open access
MHMaxime Hentzien
Maxime Hentzien
JFJaromil Frossard
Jaromil Frossard
RKRoger D. Kouyos
Roger D. Kouyos
VPVirginie Prendki
Virginie Prendki
JDJosé Damas
José Damas
TSthe Swiss HIV Cohort Study
the Swiss HIV Cohort Study
Objective: To perform an external validation of the Dat'AIDS score for predicting 5-year overall mortality among people with HIV (PWH) aged 60 years or older.Methods: This was a multi-centre prospective cohort study at all sites participating in the Swiss HIV Cohort Study (SHCS). We calculated the Dat'AIDS score in PWH aged 60 years or older at their first visit between 1 January 2015 and 1 January 2020. People living with HIV-2 and those whose Dat'AIDS score could not be calculated were excluded. Patients were followed until 1 January 2020. The primary endpoint was all-cause mortality. Vital status was collected throughout the study period. We obtained population and score descriptive statistics and assessed the score's discrimination and calibration.Results: We included 2205 participants (82% male) of median [interquartile range (IQR)] age 62.0 (60.3-67.0) years, mostly with viraemia <50 copies/mL (92.7%). Median follow-up time was 15.9 years and median (IQR) CD4 cell count at enrolment was 586 (420-782) cells/mu L. In all, 152 deaths were recorded during a total follow-up period of 7147 patient-years. The median (IQR) observed Dat'AIDS score was 3 (0-8). Discriminative capacities were good as the C-statistic was 0.73 (95% CI: 0.69-0.77) and consistent across all subgroups. Comparison of observed and expected survival probabilities showed good calibration.Conclusions: External validation of the Dat'AIDS score in patients aged 60 years or older showed that it could be a useful tool not only for research purposes, but also to identify older patients at a higher mortality risk and to tailor the most appropriate interventions.

11 May 2026 in HIV Medicine
Verified
Journal Article
Open access
CMClara Merlin
Clara Merlin
JDJosé Damas
José Damas
OTOlivier Nawej Tshikung
Olivier Nawej Tshikung
NWNoémie Wagner
Noémie Wagner
AHAnna Hachfeld
Anna Hachfeld
KDKatharine E. A. Darling
Katharine E. A. Darling
Background: Although HIV is now a chronic condition with an excellent life expectancy, some personal aspects affecting people living with HIV (PLWH), such as parenting desire, are relatively understudied. This study aimed to explore parenting desire among PLWH in Switzerland. Methods: From September 2022 until January 2024, PLWH (participants) enrolled in the Swiss HIV Cohort Study (SHCS) and followed up at seven university/cantonal hospitals were invited to complete a structured questionnaire co‐designed with patient and public involvement. There were no exclusion criteria. The questionnaire covered parenting desire, the perceived influence of HIV on family planning and whether future parenthood had ever been discussed with an HIV physician. Results: Of the 5038 PLWH attending SHCS clinic visits, 3006 (59.7%) completed the questionnaire (2974 (98.9%) complete datasets analysed). The median age was 54 years (IQR 44;61), 27% were female, 39% were men who have sex with men (MSM), 16% were of Black ethnicity, 94.5% had HIV RNA plasma viral loads <50 copies/ml. Overall, 515 participants (17.3%) expressed a desire for parenting, with a desire associated with being aged <45 years and of Black ethnicity, and 506 (17%) stated that HIV influenced family planning decisions. Discussing parenthood was associated with being female, Black, heterosexual and in a stable relationship. Among heterosexual male participants, 26.1% had ever had such discussions, compared to 6.8% of MSM. Conclusion: In this sample of PLWH, a minority expressed parenting desire, possibly due to high median participant age, and 17% felt HIV influenced family planning decisions. While female participants were more likely to have discussed future parenthood than male participants, there was a further disparity between heterosexual men and MSM. Whilst surrogacy is prohibited in Switzerland, MSM may have access to parenthood in other ways. Our findings suggest there is room for HIV physicians to proactively invite parenting discussions with all PLWH.

1 January 2023 in Revue Medicale Suisse
Verified
Journal Article
Closed access
JDJosé Damas
José Damas
ABAlexandre Berney
Alexandre Berney
MBMélanie Bieler-Aeschlimann
Mélanie Bieler-Aeschlimann
MCMatthias Cavassini
Matthias Cavassini
RPRenaud Du Pasquier
Renaud Du Pasquier
Les recommandations actuelles pour la prise en charge des troubles neurocognitifs chez les personnes vivant avec le VIH (PVVIH) comprennent une série d’...